Cargando…

Herbal Therapy Is Equivalent to Rifaximin for the Treatment of Small Intestinal Bacterial Overgrowth

OBJECTIVE: Patients with small intestine bacterial overgrowth (SIBO) have chronic intestinal and extraintestinal symptomatology which adversely affects their quality of life. Present treatment of SIBO is limited to oral antibiotics with variable success. A growing number of patients are interested i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chedid, Victor, Dhalla, Sameer, Clarke, John O., Roland, Bani Chander, Dunbar, Kerry B., Koh, Joyce, Justino, Edmundo, Tomakin, Eric, Mullin, Gerard E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Global Advances in Health and Medicine 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030608/
https://www.ncbi.nlm.nih.gov/pubmed/24891990
http://dx.doi.org/10.7453/gahmj.2014.019
_version_ 1782317411823779840
author Chedid, Victor
Dhalla, Sameer
Clarke, John O.
Roland, Bani Chander
Dunbar, Kerry B.
Koh, Joyce
Justino, Edmundo
Tomakin, Eric
Mullin, Gerard E.
author_facet Chedid, Victor
Dhalla, Sameer
Clarke, John O.
Roland, Bani Chander
Dunbar, Kerry B.
Koh, Joyce
Justino, Edmundo
Tomakin, Eric
Mullin, Gerard E.
author_sort Chedid, Victor
collection PubMed
description OBJECTIVE: Patients with small intestine bacterial overgrowth (SIBO) have chronic intestinal and extraintestinal symptomatology which adversely affects their quality of life. Present treatment of SIBO is limited to oral antibiotics with variable success. A growing number of patients are interested in using complementary and alternative therapies for their gastrointestinal health. The objective was to determine the remission rate of SIBO using either the antibiotic rifaximin or herbals in a tertiary care referral gastroenterology practice. DESIGN: One hundred and four patients who tested positive for newly diagnosed SIBO by lactulose breath testing (LBT) were offered either rifaximin 1200 mg daily vs herbal therapy for 4 weeks with repeat LBT post-treatment. RESULTS: Three hundred ninety-six patients underwent LBT for suspected SIBO, of which 251 (63.4%) were positive 165 underwent treatment and 104 had a follow-up LBT. Of the 37 patients who received herbal therapy, 17 (46%) had a negative follow-up LBT compared to 23/67 (34%) of rifaximin users (P=.24). The odds ratio of having a negative LBT after taking herbal therapy as compared to rifaximin was 1.85 (CI=0.77-4.41, P=.17) once adjusted for age, gender, SIBO risk factors and IBS status. Fourteen of the 44 (31.8%) rifaximin non-responders were offered herbal rescue therapy, with 8 of the 14 (57.1%) having a negative LBT after completing the rescue herbal therapy, while 10 non-responders were offered triple antibiotics with 6 responding (60%, P=.89). Adverse effects were reported among the rifaximin treated arm including 1 case of anaphylaxis, 2 cases of hives, 2 cases of diarrhea and 1 case of Clostridium difficile. Only one case of diarrhea was reported in the herbal therapy arm, which did not reach statistical significance (P=.22). CONCLUSION: SIBO is widely prevalent in a tertiary referral gastroenterology practice. Herbal therapies are at least as effective as rifaximin for resolution of SIBO by LBT. Herbals also appear to be as effective as triple antibiotic therapy for SIBO rescue therapy for rifaximin non-responders. Further, prospective studies are needed to validate these findings and explore additional alternative therapies in patients with refractory SIBO.
format Online
Article
Text
id pubmed-4030608
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Global Advances in Health and Medicine
record_format MEDLINE/PubMed
spelling pubmed-40306082015-05-01 Herbal Therapy Is Equivalent to Rifaximin for the Treatment of Small Intestinal Bacterial Overgrowth Chedid, Victor Dhalla, Sameer Clarke, John O. Roland, Bani Chander Dunbar, Kerry B. Koh, Joyce Justino, Edmundo Tomakin, Eric Mullin, Gerard E. Glob Adv Health Med Original Research OBJECTIVE: Patients with small intestine bacterial overgrowth (SIBO) have chronic intestinal and extraintestinal symptomatology which adversely affects their quality of life. Present treatment of SIBO is limited to oral antibiotics with variable success. A growing number of patients are interested in using complementary and alternative therapies for their gastrointestinal health. The objective was to determine the remission rate of SIBO using either the antibiotic rifaximin or herbals in a tertiary care referral gastroenterology practice. DESIGN: One hundred and four patients who tested positive for newly diagnosed SIBO by lactulose breath testing (LBT) were offered either rifaximin 1200 mg daily vs herbal therapy for 4 weeks with repeat LBT post-treatment. RESULTS: Three hundred ninety-six patients underwent LBT for suspected SIBO, of which 251 (63.4%) were positive 165 underwent treatment and 104 had a follow-up LBT. Of the 37 patients who received herbal therapy, 17 (46%) had a negative follow-up LBT compared to 23/67 (34%) of rifaximin users (P=.24). The odds ratio of having a negative LBT after taking herbal therapy as compared to rifaximin was 1.85 (CI=0.77-4.41, P=.17) once adjusted for age, gender, SIBO risk factors and IBS status. Fourteen of the 44 (31.8%) rifaximin non-responders were offered herbal rescue therapy, with 8 of the 14 (57.1%) having a negative LBT after completing the rescue herbal therapy, while 10 non-responders were offered triple antibiotics with 6 responding (60%, P=.89). Adverse effects were reported among the rifaximin treated arm including 1 case of anaphylaxis, 2 cases of hives, 2 cases of diarrhea and 1 case of Clostridium difficile. Only one case of diarrhea was reported in the herbal therapy arm, which did not reach statistical significance (P=.22). CONCLUSION: SIBO is widely prevalent in a tertiary referral gastroenterology practice. Herbal therapies are at least as effective as rifaximin for resolution of SIBO by LBT. Herbals also appear to be as effective as triple antibiotic therapy for SIBO rescue therapy for rifaximin non-responders. Further, prospective studies are needed to validate these findings and explore additional alternative therapies in patients with refractory SIBO. Global Advances in Health and Medicine 2014-05 2014-05-01 /pmc/articles/PMC4030608/ /pubmed/24891990 http://dx.doi.org/10.7453/gahmj.2014.019 Text en © 2014 GAHM LLC. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial- No Derivative 3.0 License, which permits rights to copy, distribute and transmit the work for noncommercial purposes only, provided the original work is properly cited.
spellingShingle Original Research
Chedid, Victor
Dhalla, Sameer
Clarke, John O.
Roland, Bani Chander
Dunbar, Kerry B.
Koh, Joyce
Justino, Edmundo
Tomakin, Eric
Mullin, Gerard E.
Herbal Therapy Is Equivalent to Rifaximin for the Treatment of Small Intestinal Bacterial Overgrowth
title Herbal Therapy Is Equivalent to Rifaximin for the Treatment of Small Intestinal Bacterial Overgrowth
title_full Herbal Therapy Is Equivalent to Rifaximin for the Treatment of Small Intestinal Bacterial Overgrowth
title_fullStr Herbal Therapy Is Equivalent to Rifaximin for the Treatment of Small Intestinal Bacterial Overgrowth
title_full_unstemmed Herbal Therapy Is Equivalent to Rifaximin for the Treatment of Small Intestinal Bacterial Overgrowth
title_short Herbal Therapy Is Equivalent to Rifaximin for the Treatment of Small Intestinal Bacterial Overgrowth
title_sort herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030608/
https://www.ncbi.nlm.nih.gov/pubmed/24891990
http://dx.doi.org/10.7453/gahmj.2014.019
work_keys_str_mv AT chedidvictor herbaltherapyisequivalenttorifaximinforthetreatmentofsmallintestinalbacterialovergrowth
AT dhallasameer herbaltherapyisequivalenttorifaximinforthetreatmentofsmallintestinalbacterialovergrowth
AT clarkejohno herbaltherapyisequivalenttorifaximinforthetreatmentofsmallintestinalbacterialovergrowth
AT rolandbanichander herbaltherapyisequivalenttorifaximinforthetreatmentofsmallintestinalbacterialovergrowth
AT dunbarkerryb herbaltherapyisequivalenttorifaximinforthetreatmentofsmallintestinalbacterialovergrowth
AT kohjoyce herbaltherapyisequivalenttorifaximinforthetreatmentofsmallintestinalbacterialovergrowth
AT justinoedmundo herbaltherapyisequivalenttorifaximinforthetreatmentofsmallintestinalbacterialovergrowth
AT tomakineric herbaltherapyisequivalenttorifaximinforthetreatmentofsmallintestinalbacterialovergrowth
AT mullingerarde herbaltherapyisequivalenttorifaximinforthetreatmentofsmallintestinalbacterialovergrowth